FANCD2 and familial pancreatic carcinoma: Since we found that siramesine binds equally well to the sigma-1 and sigma-2 receptor subtypes [8], we next investigated the presence of sigma-1 receptors together with the binding of FA4 for this subtype in clinically relevant pancreatic cancer cells (PANC-1 and MiaPaCa2).